← Leaderboards
Harikrishna Nakshatri
Rlr Va Medical Center
$6,069,590
Attributed
$7,545,426
Total exposure
20
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,545,426 · 18
VA$0 · 2
By mechanism
R25$2,022,919 · 2
T32$1,247,388 · 2
R01$1,173,375 · 1
R21$960,453 · 3
R03$919,874 · 6
U01$711,631 · 1
Top collaborators
- Gayle Buck3 shared
- Karl Y Bilimoria2 shared
- Tao Lu2 shared
- Kathy D Miller2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorCellsProgramsAnimal ModelMalignant Breast NeoplasmFundingCancer CellFutureResourcesClinical TrialsPathway InteractionsPharmaceutical PreparationsMemberClinicLinkMalignant Neoplasm Of LungSignal PathwayCareerResponseMediatingChemotherapyMentorsBiology
Grant awards (54)
Surgical Oncology Research Training at Indiana (SORTI)$514,022
T32 · FY2025 · CA
Educational Pathways for Cancer Research (EPCR)$392,597
R25 · FY2025 · CA · contact PI
The impact of oxygen exposure on clinical biomarkers - an underrecognized source of pre-analytic variability$355,651
U01 · FY2025 · CA · contact PI
Summer Program for Academic Research in Cancer (SPARC)$284,997
R25 · FY2025 · CA · contact PI
Cancer Research Training and Education Coordination$253,236
P30 · FY2025 · CA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Surgical Oncology Research Training at Indiana (SORTI)$411,824
T32 · FY2024 · CA
Educational Pathways for Cancer Research (EPCR)$392,597
R25 · FY2024 · CA · contact PI
The impact of oxygen exposure on clinical biomarkers - an underrecognized source of pre-analytic variability$355,980
U01 · FY2024 · CA · contact PI
Summer Program for Academic Research in Cancer (SPARC)$284,997
R25 · FY2024 · CA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Educational Pathways for Cancer Research (EPCR)$371,934
R25 · FY2023 · CA · contact PI
Summer Program for Academic Research in Cancer (SPARC)$295,797
R25 · FY2023 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$51,310
P30 · FY2023 · CA · contact PI
Mechanisms associated with systemic effects of cancer$0
I01 · FY2023 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2023 · VA · contact PI
Cancer Research Career Enhancement and Related Activities$51,310
P30 · FY2022 · CA · contact PI
Mechanisms associated with systemic effects of cancer$0
I01 · FY2022 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2022 · VA · contact PI
Cancer Research Career Enhancement and Related Activities$51,310
P30 · FY2021 · CA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2021 · VA · contact PI
Mechanisms associated with systemic effects of cancer$0
I01 · FY2021 · VA · contact PI
Cancer Research Career Enhancement and Related Activities$51,310
P30 · FY2020 · CA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2020 · VA · contact PI
Mechanisms associated with systemic effects of cancer$0
I01 · FY2020 · VA · contact PI
Impact of NF-kB methylation on chemoresistance and metastasis of breast cancer$78,534
R03 · FY2019 · CA
Cancer Research Career Enhancement and Related Activities$51,310
P30 · FY2019 · CA · contact PI
Impact of NF-kB methylation on chemoresistance and metastasis of breast cancer$78,534
R03 · FY2018 · CA
Mechanisms associated with systemic effects of cancer$0
I01 · FY2018 · VA · contact PI
Estrogen-Estrogen Receptor axis in non-transformed breast epithelial cells: studies beyond MCF-7$78,313
R03 · FY2017 · CA · contact PI
Mechanisms associated with systemic effects of cancer$0
I01 · FY2017 · VA · contact PI
Estrogen-Estrogen Receptor axis in non-transformed breast epithelial cells: studies beyond MCF-7$78,000
R03 · FY2016 · CA · contact PI
Mechanisms associated with systemic effects of cancer$0
I01 · FY2016 · VA · contact PI
Mechanisms associated with systemic effects of cancer$0
I01 · FY2015 · VA · contact PI
Anthrax Toxin Receptor as a marker and target of breast cancer stem cells$167,475
R21 · FY2012 · CA · contact PI
Persistent microRNA changes in serum of cancer-free breast cancer patients$167,475
R21 · FY2012 · CA · contact PI
Anthrax Toxin Receptor as a marker and target of breast cancer stem cells$200,970
R21 · FY2011 · CA · contact PI
Persistent microRNA changes in serum of cancer-free breast cancer patients$200,970
R21 · FY2011 · CA · contact PI
Chemoprevention of tobacco carcinogen-induced bladder cancer$74,690
R03 · FY2011 · CA · contact PI
Chemoprevention of tobacco carcinogen-induced bladder cancer$77,000
R03 · FY2010 · CA · contact PI
Cancer Biology Training Program$321,542
T32 · FY2009 · CA · contact PI
Lung Cancer Chemoprevention through LC-1$77,000
R03 · FY2009 · CA · contact PI
Lung Cancer Chemoprevention through LC-1$77,000
R03 · FY2008 · CA · contact PI
Animal Model for Local Inflammation-Induced Breast Cancer$75,750
R03 · FY2008 · CA · contact PI
Animal Model for Local Inflammation-Induced Breast Cancer$75,750
R03 · FY2007 · CA · contact PI
Chemoprevention Through Activation of Estrogen Receptor Alpha-Induced Senescence$73,553
R03 · FY2007 · CA · contact PI
Chemoprevention Through Activation of Estrogen Receptor Alpha-Induced Senescence$75,750
R03 · FY2006 · CA · contact PI
AKT MEDIATED TAMOXIFEN RESISTANCE IN BREAST CANCER CELLS$234,675
R01 · FY2005 · CA
AKT MEDIATED TAMOXIFEN RESISTANCE IN BREAST CANCER CELLS$234,675
R01 · FY2004 · CA
AKT MEDIATED TAMOXIFEN RESISTANCE IN BREAST CANCER CELLS$234,675
R01 · FY2003 · CA
AKT MEDIATED TAMOXIFEN RESISTANCE IN BREAST CANCER CELLS$234,675
R01 · FY2002 · CA
AKT MEDIATED TAMOXIFEN RESISTANCE IN BREAST CANCER CELLS$234,675
R01 · FY2001 · CA
ROLE OF IL-1 ALPHA IN METASTASIS OF BREAST CANCER$111,750
R21 · FY2001 · CA
ROLE OF IL-1 ALPHA IN METASTASIS OF BREAST CANCER$111,813
R21 · FY2000 · CA